RECRUITING

CF And Effects of Drugs Mixed Ex Vivo With Sputum for Mucolytic Treatment

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The investigators will collect samples of sputum from healthy volunteers and patients with cystic fibrosis for the purpose of: a) purifying airway mucins for plate-based binding studies and; b) assessment of the effects of carbohydrates on the rheologic properties of the sputum. This study has two hypotheses: 1. Lectins from Pseudomonas aeruginosa and Aspergillus fumigatus bind to airway mucins in a fucose-dependent manner, and this binding can be inhibited by fucosyl glycomimetic compounds. 2. Fucosyl glycomimetics will compete with Pseudomonas aeruginosa lectin (PA-IIL) and Aspergillus fumigatus lectin (AFL) and disrupt lectin-driven mucin cross-linking in CF sputum.

Official Title

CF And Effects of Drugs Mixed Ex Vivo With Sputum for Mucolytic Treatment to Lung Mucin

Quick Facts

Study Start:2012-07
Study Completion:2024-04
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT01533636

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years to 65 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:Yes
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * Healthy control subjects:
  2. * Age 18-65
  3. * No history of lung disease
  4. * Cystic fibrosis subjects:
  5. * Age 18-65
  6. * No history of lung disease other than cystic fibrosis
  7. * Diagnosis of CF if sweat chloride values \> 60 mM on two separate pilocarpine iontophoresis sweat tests and/or two allelic CF-producing mutations in genetic analysis
  1. * Use of recreational drugs within 30 days prior to enrollment
  2. * Use of tobacco within 30 days prior to enrollment, or \> 10 pack-year tobacco history
  3. * Pregnant or lactating females

Contacts and Locations

Study Contact

Xavier Orain, BS
CONTACT
415-502-3472
xavier.orain@ucsf.edu

Principal Investigator

John V Fahy, MD
PRINCIPAL_INVESTIGATOR
University of California, San Francisco

Study Locations (Sites)

University of California, San Francisco
San Francisco, California, 94143
United States

Collaborators and Investigators

Sponsor: University of California, San Francisco

  • John V Fahy, MD, PRINCIPAL_INVESTIGATOR, University of California, San Francisco

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2012-07
Study Completion Date2024-04

Study Record Updates

Study Start Date2012-07
Study Completion Date2024-04

Terms related to this study

Keywords Provided by Researchers

  • Cystic Fibrosis, Healthy

Additional Relevant MeSH Terms

  • Cystic Fibrosis